Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT00465751

Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism

Effects of Activation of the Farnesoid X Receptor (FXR) on Hepatic Lipid and Glucose Metabolism in Patients With the Metabolic Syndrome and Familial Forms of Hypertriglyceridemia

Sponsor: University Hospital, Basel, Switzerland

Conditions Familial Combined Hyperlipidemia Familial Hypertriglyceridemia Metabolic Syndrome

Interventions chenodeoxycholic acid placebo capsules

Updated 6 times since 2017 Last updated: Mar 8, 2012 Started: Oct 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Familial Combined Hyperlipidemia and Familial Hypertriglyceridemia, this trial is completed. The trial is conducted by University Hospital, Basel, Switzerland and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed Phase 0

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital, Basel, Switzerland

Data source: University Hospital, Basel, Switzerland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Basel, Switzerland